Kornimate/medical-research-clean huggingface dataset:
effect of ingesting a tomato pomace extract on platelet aggregation

Conditions: Cardiovascular Diseases

Summary: this study evaluates the acute and longer term effects of a tomato pomace extract on platelet aggregation in health subjects.

evidence from human intervention trials and mechanistic studies suggests that tomato and tomato based products are associated with a reduction in cvd risk. the mechanism by which this protective effect occurs is not clearly understood but research has focused on its potential to modulate platelet function. this single-blind, randomized, parallel design human intervention trial will recruit 99 participants to consume an orange flavoured beverage containing different doses of a tomato pomace extract (1.0 and 2.5 g) or placebo control over a 5-day period. the study aims is to investigate the effects of consuming different doses of the tomato pomace extract on platelet aggregation. safety and tolerability of the tomato pomace extracts was tested prior starting this study by undertaking a single ascending dose study.

Eligibility criteria:
inclusion criteria: * apparently healthy men aged between 18 and 26 years * bmi \>19.5 and \<26.0 * platelet aggregation response corresponding to ≥ 65% exclusion criteria: * known tomato allergy * chronic medical conditions requiring active treatment (e.g. cardiovascular disease, diabetes, asthma) * gastro-intestinal disease/disorders * smokers * medically prescribed medication known to affect platelet function * self-prescribed medication known to affect platelet function (e.g. aspirin and non-steroidal anti-inflammatory drugs) unless participant is willing to give up. * bleeding disorders (e.g. haemophilia) * dietary supplements judged to affect study outcome * parallel participation in another research project which involves dietary intervention * blood donation within 16 weeks prior to the study * depressed or elevated blood pressure measurements (\<90/50 or 95/50 if symptomatic or ≥ 160/100 mmhg) * any person related to or living with any member of the study team

Keywords: platelet aggregation
effects of age and infertility on ovarian granulosa cell function

Conditions: Infertility, Female; Infertility Unexplained; Infertility of Tubal Origin; Infertility

Summary: infertility is a life changing disorder, affecting 1 in 7 couples within the uk. treatment options pose a significant cost burden to both the nhs and patient when nhs-funded treatment options are exhausted. this highlights the need for refinements in clinical management strategies for this patient group. although there have been advancements in assisted reproductive technologies, the success rates of techniques such as in vitro fertilization (ivf) remain low. surprisingly, the ivf hormonal regimens used by most assisted conception units fail to take account of patient age, ovarian reserve or cause of infertility when deciding on treatment regimen, with a 'one size fits all' approach to treatment. the investigators propose that age and cause of infertility modify the functions and environment provided by the cells (granulosa cells) that support egg (oocyte) growth and development and understanding these changes will allow for a more personalised approach to ivf treatment regimens. the aim of this study therefore is to recruit female patients undergoing ivf with different causes of infertility and age, and harvest granulosa cells from remaining material (follicular aspirates) generated at the time of egg retrieval. granulosa cells will be cultured in vitro and cellular functions assessed. the investigators will also recruit female patients with normal fertility undergoing ivf procedure due to other reasons (i.e. egg freezing, diagnostics of genetic diseases on embryos).


Eligibility criteria:
inclusion criteria: * any woman that is: * fluent in english, * capable of giving consent, * reproductive age (between the ages of 18-45), * is hiv and hep a and hep b negative. * undergoing ivf treatment for one of the following reasons: 1. unexplained infertility 2. tubal disease 3. egg freezing 4. polycystic ovarian syndrome 5. ovulatory disorders 6. endometriosis 7. male factor infertility 8. any other cause of infertility such as fibroids. exclusion criteria: * adults unable to consent for themselves, * non-fluent english speakers, unless in clinic translators are available * aged less than 18 * is hiv or hep a or b positive, or has not undergone screening.

Keywords: ovary granulosa cells infertility ageing
rhbmp-2/crm/cd horizon® spinal system pivotal study

Conditions: Degenerative Disc Disease

Summary: the purpose of this study was to evaluate the rhbmp-2/crm/cd horizon® spinal system as a method of facilitating spinal fusion in patients with degenerative disc disease.

this clinical trial was conducted to evaluate the rhbmp-2/crm/cd horizon® spinal system for posterolateral fusion treatment of patients with symptomatic degenerative disc disease versus the control group of autogenous bone with the cd horizon® spinal system. the investigational treatment was the open bilateral posterolateral implantation of the rhbmp-2/crm/cd horizon® spinal system. one investigational implant was placed across two adjacent transverse processes on each side of the spine during the spinal fusion procedure. the control treatment was the bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the cd horizon® spinal system.

Eligibility criteria:
inclusion criteria: each patient participating in this clinical trial must meet all of the following inclusion criteria: 1. has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history of pain and radiographic studies: 2. requires fusion of a single level disc space from l1 to s1. 3. has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or tens) for a period of 6 months. 4. if of child-bearing potential, patient is non-pregnant, non-nursing, and agrees to use adequate contraception for 1 year following surgery. exclusion criteria: a patient meeting any of the following criteria is to be excluded from this clinical trial: 1. has primary diagnosis of a spinal disorder other than degenerative disc disease with grade 1 or less spondylolisthesis at the involved level. 2. had previous spinal fusion surgical procedure at the involved level. 3. requires spinal fusion at more than one lumbar level. 4. has been previously diagnosed with osteopenia. 5. has presence of active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin). 6. has a history of autoimmune disease (e.g. systemic lupus erythematosus or dermatomyositis). 7. has a history of exposure to injectable collagen or silicone implants. 8. has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhbmp 2/crm implantation. 9. has received any previous exposure to any/all bmp's of either human or animal extraction.
tertiary lymphoid structures related genes predicting prognosis in clear cell renal cell carcinoma: a retrospective cohort study

Conditions: Renal Cell Carcinoma (RCC)

Summary: the purpose of this research was to uncover the prognostic significance of tertiary lymphoid structures related genes from ccrcc patients with respect to clinical characteristics and outcomes. this offers a novel perspective on selecting populations for prostate cancer immunotherapy in future scenarios.


Eligibility criteria:
inclusion criteria: * patients diagnosed with renal cell carcinoma exclusion criteria: * incomplete medical records, inadequate follow-up information, and confirmed non-prostatic acinar adenocarcinoma
evaluation of al-78898a in exudative age-related macular degeneration

Conditions: Exudative Age-Related Macular Degeneration

Summary: the primary purpose of this study was to demonstrate a biological effect of al-78898a, as measured by change (reduction) in central subfield (csf) retinal thickness 4 weeks after a single intravitreal injection, as compared to lucentis.

the study consisted of a screening visit (visit 1), a day 0 visit (visit 2), 6 on-therapy visits at day 1, weeks 1, 2, 3, 4, and 8 (visits 3-8), and an exit visit at week 12 (visit 9). patients who met all inclusion and exclusion criteria at visit 1 were randomized in a 3:1 ratio to receive either al-78898a or lucentis as a single 50-μl injection in the study eye. additionally, patients received standard therapy for exudative amd beginning at week 2/visit 5 if the patient was not improving per protocol-specified criteria. beginning at week 4/visit 7, patients not improving received standard therapy for exudative amd at the investigator's discretion.

Eligibility criteria:
inclusion criteria: * willing to give informed consent, make the required study visits and follow instructions; * newly diagnosed with exudative age-related macular degeneration (amd); * presence of primary juxta- or subfoveal choroidal neovascularization (cnv) secondary to amd (study eye); * best-corrected visual acuity (bcva) in study eye as specified in protocol; * no vision-threatening ocular condition other than amd, in the opinion of the investigator; * other protocol-specified inclusion criteria may apply. exclusion criteria: * history or current evidence of macular or retinal disease other than exudative amd (study eye); * any evidence of fibrosis or scarring within the cnv (choroidal neovascularization)lesion (study eye); * any evidence of vitreous hemorrhage (study eye); * history or evidence of surgery (study eye), as specified in protocol; * any active systemic infection or ocular/intraocular infection or inflammation in either eye; * a history or current medical diagnosis of glaucoma or ocular hypertension (study eye), as specified in protocol; * history or current evidence of a medical condition that may in the opinion of the investigator preclude the safe administration of test article, adherence to the scheduled study visits, safe participation in the study or affect the results of the study * history of severe or serious hypersensitivity to any component of the investigational product, reference product or clinically relevant sensitivity to fluorescein dye, as assessed by the investigator; * females of childbearing potential may not participate in the study if pregnant, lactating, or not using adequate birth control methods for the duration of the study; * participation in any ocular or non-ocular investigational study within 30 days of screening; * has received any approved or investigational therapy for amd in the study eye with the exception of vitamins; * other protocol-defined exclusion criteria may apply.

Keywords: wet amd intravitreal injection macular degeneration vegf treatment
prognostic value of the amr measured after ppci in stemi patients

Conditions: Coronary Heart Disease; ST Elevation Myocardial Infarction

Summary: the goal of this observational study is to learn about in stemi with primary pci patients. the main questions it aims to answer are: * to determine the value of amr in predicting the long-term clinical prognosis of patients with stemi after ppci, and to find the best cut-off value. * analyze the factors of ppci affecting amr and explore the effective measures of ppci microcirculation protection. radiographic images of stemi receiving primary pci treatment in several chest pain centers in china will be included. the last image of the infarct-related vessel will be used as a target to calculate its amr. the relationship between amr and long-term clinical prognosis was analyzed.


Eligibility criteria:
inclusion criteria: * aged 18 or older * type 1 myocardial infarction * receive ppci exclusion criteria: * failed to identify culprit vessels. * structural heart disease with moderate to severe aortic valve or mitral regurgitation and or stenosis that may affect cardiac function * dialysis patients with severe renal insufficiency * severe and uncontrollable arrhythmia * complicated with dilated cardiomyopathy * unable to tolerate dual antiplatelet therapy * severe and uncontrollable anemia * hyperthyroidism * timi blood flow 0-1 grade after ppci
n. meningitidis carriage study

Conditions: Infections, Meningococcal

Summary: this carriage study aims to evaluate the presence of meningococcus in asian populations (and potential for disease) and explore the extent and serogroup distribution of meningococci circulating in the population.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes can and will comply with the requirements of the protocol or subjects who the investigator believes that parent(s)/legally acceptable representative(s) \[lar(s)\] can and will comply with the requirements of the protocol. * written informed consent obtained from the subject/from the parent(s)/lar of the subject. * asymptomatic subjects attending a school or university. * a male or female between, and including 5 and 24 years of age at the time of enrollment. exclusion criteria: * subjects who have received a meningococcal conjugate vaccine. * use of any investigational or non-registered product within one week before the enrollment visit. * acute respiratory tract infection within 14 days of sample collection. * immune deficiencies, haematological disorders and oncological disease. * use of steroids or immunosuppressant drugs within 14 days of sample collection. * administration of antibiotics within the 2 weeks preceding the collection of sample. * cranio-facial malformations prohibiting the collection of posterior pharyngeal swabs. * child in care.

Keywords: neisseria meningitidis philippines carriage meningococcus
social media for art adherence and retention in adolescents and young adults: the vijana-smart study

Conditions: HIV-1-infection; Adherence, Medication; Depression

Summary: the goal of this study is to investigate whether a virtual peer support group improves art knowledge, adherence, and mental health in youth living with hiv in kenya.

adolescents and young adults (aya) living with hiv show lower art adherence, higher loss to follow-up and higher aids-related mortality than other age groups. innovative approaches are needed that address aya's unique needs and improve their adherence and retention in hiv care. there is evidence that peer support and mobile messaging with healthcare workers (hcw) are two strategies that may be effective in this group, but their evaluation has been limited and no interventions have combined them. since 2014, youth-run virtual support groups have spontaneously started at hiv clinics, using the mobile social media application whatsapp. these groups present valuable case studies from which the proposed project will develop a structured social media intervention that combines peer and hcw support to improve art adherence and retention, guided by the preferences of aya. the specific aims are to (1) characterize the existing whatsapp groups through in-depth interviews with members and detailed content analysis of the group's communications during a 6-week observation period. this will define the elements and features desired by aya in a social media intervention. (2) guided by findings from aim 1, behavioral theory, and the study team's ongoing research on mobile messaging to improve art adherence, to develop and refine structured content for a reproducible whatsapp intervention that incorporates peer and hcw interaction. (3) pilot the structured intervention for 6 months in another clinic and evaluate its impact on intermediate outcomes art knowledge, depression and stigma.

Eligibility criteria:
inclusion criteria: * living with hiv * on art * aware of hiv status * has access to whatsapp * literate
yoga in the treatment of adolescent idiopathic and degenerative scoliosis

Conditions: Scoliosis; Scoliosis Idiopathic

Summary: the effect of two isometric exercises is measured on cobb angles from films taken 4-10 months apart.

the investigators obtained baseline cobb angles on simple and complex curves, and collected previous, earlier studies of each adolescent idiopathic and degenerative scoliosis patient. the investigators then taught them to do the side-plank pose with the convex side of lumbar and thoracolumbar scoliotic curves downward, and a slightly altered version of the the half moon pose of yoga with the convex side of thoracic and cervicothoracic curves downward. the half moon pose was altered in that a belt was looped around the horizontal leg's foot, and held in a vertically extended upper arm's hand, and pulled tightly in that vertical position. each pose was held as long as the patient could at least once daily. cobb angles were again measured in films taken 4-10 months later.

Eligibility criteria:
inclusion criteria: * scoliosis * willingness to do pose at least once daily for 4 -10 months * willingness to have a second x-ray 4-10 months after starting to do pose exclusion criteria: * neuromuscular disease * previous spinal surgery * pregnancy
genetic research of monogenic obesity in a pediatric cohort with severe and early onset obesity

Conditions: Monogenic Obesity

Summary: obesity is a frequent disease mainly caused by environmental/polygenic factors and more rarely caused by the alteration of a single gene ("monogenic obesity"). the diagnosis of these rare forms can lead to personalized management (new treatments, prognosis, adapted hygienic and dietary rules) and family screening. the use of a panel covering the known causes of monogenic obesity on a pediatric cohort of severe and early obesity will allow to evaluate the relevance of these analyses to adapt the management of this type of patients.


Eligibility criteria:
inclusion criteria: * recruitment age: 2-17 years * body mass index, greater than the international obesity task force (iotf) 30 curve before the age of 5 * care at the specialized pediatric obesity center (cso) of the bordeaux university hospital * informed consent signed exclusion criteria: * no informed consent

Keywords: monogenic obesity pediatric early onset obesity genetic disease
autologous micro-fragmented adipose tissue injection for knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: knee osteoarthritis (oa) is characterized by loss of cartilage leading to instability, reduced range of motion, and functional limitations. current treatment has various limitations so that alternative options to restore function and alleviate joint pain, with the ultimate goal of healing damaged articular cartilage are needed. mesenchymal stem cells (mscs) therapy has shown promising results. however, mscs are limited by complex regulatory issues. lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue through mild mechanical force. this procedure is enzyme free and requires no clonal expansion or manipulation. the goal of this study is to evaluate the possible benefits of reduced joint pain and increased joint functionality in patients with knee osteoarthritis after the injection of lipogems.


Eligibility criteria:
inclusion criteria: * age of eighteen or older * diagnosis of symptomatic knee osteoarthritis * radiographic evidence of knee osteoarthritis * failure of conservative treatment exclusion criteria: * treatment with any intra-articular knee injection within 8 weeks before surgery * any disease or condition potential to interfere study outcome * under 18 years of age
illness management and parental adjustment to cancer treatment

Conditions: Solid Tumor; Leukemia; Lymphoma; Brain Tumor

Summary: the purpose of this study is to test the efficacy of a clinic-based intervention designed to reduce illness uncertainty for parents of children who have been recently diagnosed with cancer.

the proposed trial will test the efficacy of the parent-focused clinic-based parent uncertainty management intervention (pumi) to improve the outcomes of children newly diagnosed with cancer and their parents. participants will be randomly assigned to receive equivalent doses of either the pumi or an education/support (eso) group. theoretically driven by mishel's model of illness uncertainty, the pumi will teach parents about uncertainty prevention and management through the use of medically-specific communication, information management, and problem-solving skills via in-clinic sessions and an online portal. parents and children will complete measures online at baseline, 1-week, and 3-, 6-, and 12-month follow-ups.

Eligibility criteria:
inclusion criteria: * the child has been diagnosed with leukemia or lymphoma, malignant solid tumor, or malignant brain tumor * the child is being treated for cancer and returning to the medical center (cchmc or ouhsc). * the child is 18 years of age or younger * recruitment occurs within 2-12 weeks post diagnosis * the parent is responsible for care and is willing to give consent and participate * the child is willing to give assent or consent and participate (only for children 8 years old and older) * the parent gives patient permission to participate. * parent is fluent in english exclusion criteria: * the child is experiencing an imminent medical crisis necessitating significant medical intervention * the child with cancer is determined to be in the terminal phase of illness and/or is receiving end of life care * the diagnosis is determined to be a relapse or a second malignancy * the parent is currently being treated for a serious psychiatric disorder, or, evidences mental retardation * the parent is younger than 18 years of age * the parent is not english speaking * the parent is unwilling to give written permission for child participation * if the patient's treatment visit schedule is too infrequent to meet the study visit timeline requirements

Keywords: intervention illness uncertainty childhood cancer solid tumor leukemia lymphoma brain tumor randomized clinical trial parental uncertainty management intervention parent oncology pediatric
stevia extract and glucose homeostasis

Conditions: Overweight; Obesity

Summary: this study aims to assess the effect of stevia extract on postprandial glucose and insulin levels in overweight and obese adults when compared to sugar and water.

the study is a three-arm crossover trial involving participants attending the lab on 3 different occasions (separated by 3-5 day washout period), where they will be administered water, sugar solution (65g), water and stevia extract (5g) solution. the solution will be followed by a consumption of a fixed meal (after 30 minutes). breakfast will be standardised. capillary blood glucose will be collected every 30 min until 2 hours post meal. venous blood samples will be collected before the intake of the solution and at 2 hours after meal intake.

Eligibility criteria:
inclusion criteria: * age 18-65 years * bmi 27-40 kg/m2 * males and females exclusion criteria: * athletes * pregnant or breastfeeding women * patients with chronic disease (diabetes, cvd etc...).

Keywords: non-nutritive sweeteners postprandial glucose diabetes obesity satiety